OBJECTIVE: Intrathecal IgG synthesis, persistence of bands of oligoclonal IgG, and memory B-cell clonal expansion are well-characterized features of the humoral response in multiple sclerosis (MS). Nevertheless, the target antigen of this response remains enigmatic. METHODS: We produced 53 different human IgG1 monoclonal recombinant antibodies (rAbs) by coexpressing paired heavy- and light-chain variable region sequences of 51 plasma cell clones and 2 B-lymphocyte clones from MS cerebrospinal fluid in human tissue culture cells. Chimeric control rAbs were generated from anti-myelin hybridomas in which murine variable region sequences were fused to human constant region sequences. Purified rAbs were exhaustively assayed for reactivity against myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein by immunostaining of transfected cells expressing individual myelin proteins, by protein immunoblotting, and by immunostaining of human brain tissue sections. RESULTS: Whereas humanized control rAbs derived from anti-myelin hybridomas and anti-myelin monoclonal antibodies readily detected myelin antigens in multiple immunoassays, none of the rAbs derived from MS cerebrospinal fluid displayed immunoreactivity to the three myelin antigens tested. Immunocytochemical analysis of tissue sections from MS and control brain demonstrated only weak staining with a few rAbs against nuclei or cytoplasmic granules in neurons, glia, and inflammatory cells. INTERPRETATION: The oligoclonal B-cell response in MS cerebrospinal fluid is not targeted to the well-characterized myelin antigens myelin basic protein, proteolipid protein, or myelin oligodendrocyte glycoprotein.
OBJECTIVE: Intrathecal IgG synthesis, persistence of bands of oligoclonal IgG, and memory B-cell clonal expansion are well-characterized features of the humoral response in multiple sclerosis (MS). Nevertheless, the target antigen of this response remains enigmatic. METHODS: We produced 53 different human IgG1 monoclonal recombinant antibodies (rAbs) by coexpressing paired heavy- and light-chain variable region sequences of 51 plasma cell clones and 2 B-lymphocyte clones from MS cerebrospinal fluid in human tissue culture cells. Chimeric control rAbs were generated from anti-myelin hybridomas in which murine variable region sequences were fused to human constant region sequences. Purified rAbs were exhaustively assayed for reactivity against myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein by immunostaining of transfected cells expressing individual myelin proteins, by protein immunoblotting, and by immunostaining of human brain tissue sections. RESULTS: Whereas humanized control rAbs derived from anti-myelin hybridomas and anti-myelin monoclonal antibodies readily detected myelin antigens in multiple immunoassays, none of the rAbs derived from MS cerebrospinal fluid displayed immunoreactivity to the three myelin antigens tested. Immunocytochemical analysis of tissue sections from MS and control brain demonstrated only weak staining with a few rAbs against nuclei or cytoplasmic granules in neurons, glia, and inflammatory cells. INTERPRETATION: The oligoclonal B-cell response in MS cerebrospinal fluid is not targeted to the well-characterized myelin antigens myelin basic protein, proteolipid protein, or myelin oligodendrocyte glycoprotein.
Authors: Gregory P Owens; Kimberly M Winges; Alanna M Ritchie; Sydni Edwards; Mark P Burgoon; Laura Lehnhoff; Kirsten Nielsen; John Corboy; Donald H Gilden; Jeffrey L Bennett Journal: J Immunol Date: 2007-11-01 Impact factor: 5.422
Authors: Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith Journal: N Engl J Med Date: 2008-02-14 Impact factor: 91.245
Authors: Esther C W Breij; Bianca P Brink; Rob Veerhuis; Christa van den Berg; Rianka Vloet; Riqiang Yan; Christine D Dijkstra; Paul van der Valk; Lars Bö Journal: Ann Neurol Date: 2008-01 Impact factor: 10.422
Authors: Mark P Burgoon; Randall J Cohrs; Jeffrey L Bennett; Sarah W Anderson; Alanna M Ritchie; Sabine Cepok; Bernhard Hemmer; Don Gilden; Gregory P Owens Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Shalina S Ousman; Beren H Tomooka; Johannes M van Noort; Eric F Wawrousek; Kevin C O'Connor; David A Hafler; Raymond A Sobel; William H Robinson; Lawrence Steinman Journal: Nature Date: 2007-06-13 Impact factor: 49.962
Authors: Barbara Serafini; Barbara Rosicarelli; Diego Franciotta; Roberta Magliozzi; Richard Reynolds; Paola Cinque; Laura Andreoni; Pankaj Trivedi; Marco Salvetti; Alberto Faggioni; Francesca Aloisi Journal: J Exp Med Date: 2007-11-05 Impact factor: 14.307
Authors: Emily K Mathey; Tobias Derfuss; Maria K Storch; Kieran R Williams; Kimberly Hales; David R Woolley; Abdulmonem Al-Hayani; Stephen N Davies; Matthew N Rasband; Tomas Olsson; Anja Moldenhauer; Sviataslau Velhin; Reinhard Hohlfeld; Edgar Meinl; Christopher Linington Journal: J Exp Med Date: 2007-09-10 Impact factor: 14.307
Authors: Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson Journal: Acta Neuropathol Date: 2016-10-11 Impact factor: 17.088
Authors: Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani Journal: Nat Rev Neurol Date: 2013-03-26 Impact factor: 42.937
Authors: Kevin Blauth; John Soltys; Adeline Matschulat; Cory R Reiter; Alanna Ritchie; Nicholas L Baird; Jeffrey L Bennett; Gregory P Owens Journal: Acta Neuropathol Date: 2015-10-28 Impact factor: 17.088
Authors: Mara Catani; Denise Walther; Michael R Christie; Kerry A McLaughlin; Ezio Bonifacio; Anne Eugster Journal: Diabetologia Date: 2016-02 Impact factor: 10.122
Authors: Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs Journal: J Virol Date: 2012-10-17 Impact factor: 5.103